baber/WOPTO huggingface dataset:
Patent NZ-536909-A (NZ)
Title: Target nucleic acid conjugating system comprising a solid support having a tag oligonucleotide covalently bound to the surface of the solid support
Inventor: POETTER KARL FREDERICK
IPC: C12Q1/68
Filed: 2003-06-04
Abstract: Described is an anchoring system that generally comprises a solid support and a chemical linking moiety useful for ether formation with another chemical moiety on a nucleic acid molecule. Further contemplated are methods for anchoring a nucleic acid molecule to a solid support via a covalent linkage. The anchoring system is useful in construction of nucleic acid arrays, to purify nucleic acid molecules and to anchor nucleic acid molecules so that they can be used as templates for in vitro transcription and/or translation experiments and to participate in amplification reactions. The anchoring system is particularly adaptable for use with microspheres and the preparation of microsphere suspension arrays and optical fibre arrays. The anchoring system permits the generation of an anchored oligonucleotide for use as a universal nucleic acid conjugation substrate for any nucleic acid molecule or population of nucleic acid molecules. Further provided is a kit useful for anchoring nucleic acid molecules or comprising nucleic acid molecules already anchored to a solid support. The figure is a diagrammatic representation showing ligase-mediated customisation phosphorylated target DNA and bridge DNA is mixed with tagged microspheres, T4 DNA ligase, and ATP. After brief reaction at room temperature, bridge and unincorporated targets are removed by heat and separation from the microspheres.
Patent NZ-538303-A (NZ)
Title: Injection grouting
Inventor: GREENWOOD PETER
IPC: C09K107/00
Filed: 2003-08-05
Abstract: The invention relates to the use of a composition for injection grouting obtainable by mixing an alkali metal silicate or an organic silicate, colloidal silica particles, and at least one gelling agent, wherein the weight ratio of colloidal silica to silicate is from about 2:1 to about 100:1. The invention also relates to a method of sealing a leaking part or cavity, and method of cutting off a liquid flow in a leaking part or cavity. The invention further relates to a composition for injection grouting and a method for preparing such composition.
Patent NZ-540778-A (NZ)
Title: Non-pegylated long-circulating liposomes
Inventor: DAFTARY GAUTAM VINOD
IPC: A61K9/127
Filed: 2003-12-31
Abstract: Along circulating non-pegylated liposomal doxorubicin composition for parenteral administration and a process for its preparation. The circulation time in swiss albino mice is at least 25 times longer than conventional non-liposomal compositions. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.
Patent NZ-541239-A (NZ)
Title: Process for micronizing materials
Inventor: ARNOLD CHARLES A
IPC: C01B31/02
Filed: 2002-08-30
Abstract: A powdered form of amorphous carbon comprising particles that when dispersed in water are characterized by essentially 100% of the particles being about 5 microns or less and by about 90% of the volume of the particles being about 1 micron or less. (62) Divided out of 531480
Patent NZ-543410-A (NZ)
Title: Carrier complexes comprising at least one molecule and an aromatic cationic peptide that can cross cell membranes by an energy-independent mechanism and deliver the molecules inside the cell
Inventor: SZETO HAZEL
IPC: A61K9/127
Filed: 2004-05-03
Abstract: Provided is the use of a carrier complex in the manufacture of a medicament for delivering a molecule to a cell, wherein the carrier complex comprises the molecule and an aromatic cationic peptide, wherein the aromatic cationic peptide comprises: (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of ten amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm, is the largest number that is less than or equal to r + 1; and (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a is the largest number that is less than or equal to pt + 1, except that when a is 1, pt may also be 1. Further provided are corresponding carrier complexes and methods of delivering a molecule to a plant or bacterial cell using the carrier complex.
Patent NZ-544174-A (NZ)
Title: Pharmaceutical formulation comprising levothyroxine sodium
Inventor: KONIECZNA MALGORZATA
IPC: A61K31/198
Filed: 2004-07-08
Abstract: Disclosed is a pharmaceutical formulation comprising: (a) an effective amount of levothyroxine sodium, (b) microcrystalline cellulose which has a mean particle size of less than 125 micometers and is present in an amount of 60 to 85% w/w based upon the total weight of the formulation, and (c) pregelatinised starch present in an amount of 5 to 30% w/w based upon total weight formulation.
Patent NZ-548457-A (NZ)
Title: Process for producing lactoperoxidase
Inventor: ICHIHASHI NOBUO
IPC: B01J49/00
Filed: 2005-02-08
Abstract: Provided is a process for producing lactoperoxidase comprising: a step (1) for bringing one or more milk materials into contact with a cation exchanger having weakly acidic groups as ion exchange groups to thereby effect adsorption treatment; a step (2) for washing the cation exchanger after said adsorption treatment; a step (3) for bringing said washed cation exchanger into contact with a leaching solvent which elutes lactoperoxidase, to thereby obtain a leaching solution having lactoperoxidase eluted into said leaching solvent; a step (4) for concentrating said leaching solution through an ultrafiltration membrane to thereby effect precipitation in the concentrated leaching solution; and a step (5) for obtaining a lactoperoxidase solution by removing the precipitation from said concentrated leaching solution. Further provided is a similar process wherein the purity of solid lactoperoxidase s 80% or more.
Patent NZ-550786-A (NZ)
Title: Computationally asymmetric cryptographic systems
Inventor: TULIANI JONATHAN ROSHAN
IPC: H04L9/32
Filed: 2005-02-04
Abstract: Methods, apparatus and computer program code for a computationally asymmetric hash function, in particular for use with symmetric cryptographic algorithms are described. A method of determining a computationally asymmetric hash function value is provided; the method includes the steps of: -determining a computationally asymmetric hash function J using a cryptographic hash function and a time-lock puzzle for computing an intermediate value L computable by a first method and a second method, with each of the first and second methods employing at least one common first parameter N, with the first method being intrinsically sequential to compute the intermediate value L and with the second method additionally employing at least one second parameter E whereby the second method is not intrinsically sequential and the second method is computationally faster than the first method, - computing the result of the computationally asymmetric hash function J of the data to be signed, using the first method to compute the intermediate value L, and - encrypting the result to provide the electronic signature for the data.
Patent NZ-555778-A (NZ)
Title: Compositions and methods for reducing the transmissivity of illnesses
Inventor: ROSENBLOOM RICHARD A
IPC: A61K36/9068
Filed: 2005-12-14
Abstract: Disclosed is the use of a first ingredient selected from the group consisting of ginger extract, ginger powder, at least a part of a whole plant of ginger, a ginger tincture, one or more compounds contained in ginger, and mixtures thereof; and a second ingredient selected from the group consisting of green tea powder, green tea extract, at least a part of a whole plant of green tea, tinctures of green tea, one or more compounds contained in green tea, and mixtures thereof; for the manufacture of a medicament to reduce the probability of contracting an illness caused by a virus in a mammal or a bird that had not contracted the illness at the time of administration of said medicament.
Patent NZ-562783-A (NZ)
Title: Method of reducing greenhouse gas production
Inventor: DUNCAN KELVIN
IPC: A23K1/16
Filed: 2007-10-24
Abstract: Disclosed is a method of suppressing methanogen archaea activity in a non-human animal by the step of introducing an extract derived from the plant species Impatiens balsamina into an environment in which methanogen archaea are present in the non-human animal.
Patent NZ-567280-A (NZ)
Title: Anti-theft safety system for a portable, manually operated tool, and the adapted tool of the system
Inventor: CALVET PIERRICK
IPC: B25F5/00
Filed: 2006-10-12
Abstract: A portable, manually operated tool 1 comprising a module 5 for electronically locking/unlocking the tool 1 in order to block or authorise its use. The module is configured to be switched from a locked state to an unlocked state by an electronic unlocking key transmitted to the tool by a control module 8 in a control station 20 of a tool anti-theft safety system of which the tool 1 forms a part. The tool 1 further includes a diagnostic module 11 for after-sales service and a connecting circuit 14 in order to connect the tool 1 to an after-sales station, to ensure loading of the key.
Patent NZ-568767-A (NZ)
Title: A shearing comb
Inventor: COOPER RONALD GEORGE
Filed: 2008-05-30
Abstract: A shearing comb (10) suitable for use with a sheep shearing handpiece includes a plurality of inner teeth (12) spaced apart between a pair of outermost teeth (12'). Some of the inner teeth, but not the outermost teeth, include a prominent skid (14) to leave a thicker layer of wool than normal. The skid may be in the form of an upwardly projecting fin.
Patent NZ-569326-A (NZ)
Title: Method and device for drying a gas coming from a compressor with a counterflow of gas during compressor idle time
Inventor: VANDERSTRAETEN BART ETIENNE AGNES
IPC: B01D53/04
Filed: 2007-01-04
Abstract: Disclosed is a method for drying gas coming from a compressor (2). The gas is directed through a drier (5) of the type which consists of an air receiver (6) and a rotatable drying element (9). In the drier has been provided an adsorption and/or absorption medium (10) which is alternately guided through a drying zone (7) and a regeneration zone (8) of the air receiver. During periods of standstill or of idle running of the compressor a gas flow is guided counterflow through the adsorption and/or absorption medium in the drying zone, in a flow direction (P) from the outlet (22) to the inlet (15) of the drying zone.
Patent NZ-575240-A (NZ)
Title: A cart with a storage section comprising at least one inclined shelf whose upper end is arranged at a loading end
Inventor: THOGERSEN LARS
IPC: B65G67/00
Filed: 2007-08-17
Abstract: A cart (100) for transport and storage of items is disclosed. The cart (100) comprises a chassis (104) with plurality of wheels (106). The wheels (106) are arranged to make contact with an essentially horizontal supporting surface. The cart (100) further includes a storage section (102). The storage section (102) comprises at least one shelf (108) that is inclined with respect to the supporting surface, and a releasable closure structure (118) located at the lower end of the shelf (108). The shelf (108) defines an upper end and a lower end. The upper end of the shelf (108) is arranged at a loading end (114) of the cart and the lower end is arranged at an unloading end (116) of the cart (100). The closure structure (118) has a closing position in which it retains items supported by the shelf (108) in the cart (100) and an opening position in which the items may be removed from the cart (100) at the lower end of the shelf (108). The at least one shelf (108) extends longitudinally in the storage section (102) between the upper end and the lower end. This allows the items to be automatically conveyed from the loading end (114) to the unloading end (116) of the cart (100) under the action of gravity.
Patent NZ-578876-A (NZ)
Title: 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
Inventor: LI HUI
IPC: A61K31/4162
Filed: 2008-02-04
Abstract: Disclosed are 5-{ [piperazin-1-yl]carbonyl} -3-{ (pyridin-2-yl)amino} -1,4,5,6-tetrahydro-pyrrolo[3,4-c]pyrazole derivatives as represented by the general formula (A), wherein X is C-R11 or N; A and B are selected from C or N, provided that both A and B are not N; and wherein the remaining substituents are as defined herein. Representative compounds include N4-(6,6-dimethyl-5-{ [(2S)-2,4,5,5-tetramethylpiperazin-1-yl]carbonyl} -1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)-N2-ethyl-5-fluoropyrimidine-2,4-diamine, N2-ethyl-5-fluoro-N4-(5-{ [(2S,5R)-4-(3-methoxypropyl)-2,5-dimethylpiperazin-1-yl]carbonyl} -6,6-dimethyl-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)pyrimidine-2,4-diamine acetate salt. Further disclosed is a pharmaceutical composition which comprises an effective amount of a compound as defined above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for treating diabetes mellitus and one or more of its complications, cancer, ischemia, inflammation, a central nervous system disorder, cardiovascular disease, Alzheimer's disease, dermatological disease progression, a virus disease or an inflammatory disorder.
Patent NZ-592098-A (NZ)
Title: Indirect and direct method of sequestering contaminates
Inventor: NEUMANN DAVID KURT
IPC: B01D53/14
Filed: 2009-09-28
Abstract: 592098 Disclosed is a method of sequestering gas phase molecules with the following steps. A number of liquid jets each forming a planar coalesced sheet of slurry. The jets arranged in parallel planes along the length of a slurry conduit. A gas with gas phase molecules passes through the coalesced sheets of slurry. The gas phase molecules are mineralized by a mass transfer interaction between the planar coalesced sheets of slurry and the gas phase molecules.
Patent NZ-593226-A (NZ)
Title: Gene expression markers (efnb2) for colorectal cancer prognosis
Inventor: COWENS WAYNE
IPC: C12Q1/68
Filed: 2007-01-11
Abstract: Disclosed is a method of predicting clinical outcome for a human subject following surgical resection of colorectal cancer, the method comprising: a.) Determining a normalised level of RNA transcript of EFNB2, or an expression product thereof, in a biological sample comprising cancer cells obtained from said human subject; and b.) Predicting the likelihood of a positive clinical outcome for said human subject by comparing said normalised level to gene expression data obtained from colorectal cancer reference samples derived from patients with colorectal cancer, wherein increased normalised level of an RNA transcript of EFNB2, or an expression product thereof, is negatively correlated with an increased likelihood of a positive clinical outcome.
Patent NZ-594461-A (NZ)
Title: Method and device for dispensing sealant within a gap
Inventor: VAN ERDEN DONALD L
IPC: B29C48/30
Filed: 2010-01-14
Abstract: 594461 A nozzle head for dispensing sealant within a gap in an application direction, the nozzle head comprising: a body section (159) forming a primary channel (161) through which the sealant is dispensed, the primary channel forming an entrance through which sealant enters the body section and an exit (169) through which sealant is dispensed from the nozzle head; a port (160) connected with the body section and surrounding the exit, the port forming a chamber (171) having a tip portion (165) opposed to a rear opening (164); and a nose (156) connected with the body section adjacent the tip portion. The chamber forms an angled path (162) from the tip portion to the rear opening to trap and guide excess sealant dispensed from the nozzle head within the chamber from the tip portion out through the rear opening. When the sealant is dispensed from the nozzle head within the gap in the application direction, the tip portion is located upstream from the exit and the rear opening is located downstream from the exit. The nose includes a first surface (157), and a second surface (158), the first surface of the nose extending in a first plane and the second surface of the nose extending in a second plane, such that an engagement angle is formed between the first and second planes for bridging at least a portion of the gap and guiding sealant into the gap. First and second wings (152,154) extend from opposing sides of the port for bridging the gap, the first wing being connected with the second wing to form the tip portion.
Patent NZ-597089-A (NZ)
Title: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
Inventor: ROSARIO-JANSEN THERESA
IPC: A61K38/00
Filed: 2010-06-25
Abstract: 597089 Disclosed is a method for diagnosing the risk of infusion reactions in a patient undergoing PEGylated uricase therapy, comprising the steps of: determining uric acid levels in a biological sample obtained from said patient at least 2 hours after administration of PEGylated uricase, wherein a uric acid level of more than 4mg/dl indicates that said patient is at risk of infusion reactions and PEGylated uricase therapy is to be discontinued. Further disclosed is a method to predict whether a patient will develop infusion reaction after undergoing PEGylated uricase therapy, said method comprising the steps of: determining uric acid levels in a biological sample obtained from said patient at least 2 hours after administration of PEGylated uricase, wherein maintenance of a uric acid level at less than 4mg/dl indicates said uric acid level is associated with a lower likelihood of infusion reaction or wherein a uric acid level of at least 4mg/dl in said determined uric acid level indicates a higher likelihood of infusion reaction at a time point, when the uric acid level is measured. Further disclosed is a method to predict whether a patient will develop antibody-mediated PEGylated uricase clearance after being treated with PEGylated uricase without measuring anti-PEGylated uricase and anti-PEG antibodies titer, comprising the steps of: determining uric acid levels in a biological sample obtained from said patient at least 2 hours after administration of PEGylated uricase, wherein maintenance of a level at less than 4mg/dl indicates that uric acid level is associated with a lower likelihood of antibody-mediated PEGylated uricase clearance or wherein a uric acid level of at least 4mg/dl indicates that said determined uric acid level is associated with a higher likelihood of antibody-mediated PEGylated uricase clearance at a time point when said uric acid level is measured.
Patent NZ-598692-A (NZ)
Title: Siren
Inventor: MENOR ADAM R
IPC: G10K7/06
Filed: 2010-08-03
Abstract: 598692 Disclosed is a compressed air or gas operated siren for generating an audio warning noise, signal or sound under extreme operating conditions. The siren includes a base having a central axis and a peripheral wall circumscribed about the central axis to define an internal chamber. The peripheral wall includes a plurality of apertures in communication with the internal chamber. A rotor is disposed within the chamber and centrally aligned with the axis. The rotor includes a plurality of spaced apart fins radially disposed about the axis, each of the plurality of fins having an outermost portion at a peripheral edge of the rotor and an innermost portion located between the axis and the peripheral edge. An external housing cooperates with the base to enclose the rotor within the internal chamber, the external housing including a first plurality of ports and a second plurality of ports, the first and second plurality of ports being in fluid communication with the internal chamber of the base. A driver is coupled to the rotor and is powered by a supply of carbon-dioxide gas to rotate the rotor about the axis at a rotational speed such that external air is drawn through the first plurality of ports, into the chamber and out the second plurality of ports so as to generate an alarm sound having an intensity greater than 100 decibels (100 dB).
Patent NZ-602200-A (NZ)
Title: Assembly and method for reducing nitrogen oxides, carbon monoxide and hydrocarbons in exhausts of internal combustion engines
Inventor: GEHRET JOSEPH B
IPC: F01N3/00
Filed: 2010-10-28
Abstract: An assembly (10) and method for reducing nitrogen oxides, carbon monoxide and hydrocarbons in exhausts of internal combustion engines, wherein the exhaust is acted upon in a first stage catalytic converter (24). A first portion of the first stage catalytic converter output is cooled and a second portion of the catalytic converter output is not cooled. The cooled and not cooled exhausts are united and directed to a second stage catalytic converter (46). Air is injected into a selected one of the not cooled exhaust prior to the juncture thereof with the cooled exhaust, and the combined cooled and not cooled exhausts after the juncture thereof.
Patent NZ-616456-A (NZ)
Title: Triazolopyridine compounds as mps-1 inhibitors
Inventor: BRIEM HANS
IPC: C07D471/04
Filed: 2012-04-16
Abstract: Provided are triazolopyridine derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include N,N-diethyl-4-{ [6-(4-{ [(4-fluorophenyl)acetyl]amino} pheny1)[1,2,4]triazolo[1,5-a]pyridin-2-yl]amino} -3-methoxybenzamide and N-( 4-fluorobenzyl)-4-(2-{ [4-(hydroxymethyl)-2-methoxyphenyl]amino} [1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide. The compounds are inhibitors of monopolar spindle 1 (Mps-1) kinase also known as tyrosine threonine kinase (TTK). The compounds may be useful in the treatment of cancer.
Patent NZ-618596-A (NZ)
Title: Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents
Inventor: MCCHESNEY JAMES D
IPC: C07D407/12
Filed: 2012-06-05
Abstract: The present disclosure an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof. The conjugate may be with a drug selected from taxanes, abeo-taxanes, camptothecins, epothilones, cucurbitacins, quassinoids, anthracyclines, and their analogs and derivatives.
Patent NZ-623708-A (NZ)
Title: Interface for fuel delivery system for combustion nailer
Inventor: LARGO MARC
IPC: B25C1/08
Filed: 2012-10-12
Abstract: A fuel delivery system for use with a combustion nailer (10) including a cylinder head frame (40,50), the delivery system includes a fuel cell (60) with an outer shell (68) having a closed lower end (92) and an open upper end, a closure (70) crimped over the upper end and defining an opening for accommodating a reciprocating valve stem (64), a fuel cell adapter (80) frictionally engaging the closure and including a flange (90) configured for suspending the fuel cell in the fuel cell chamber (16). The diameter of the flange is greater than that of the fuel cell. A stem receiver block is connectable to the cylinder head frame and includes a stem engagement portion configured for directly and sealingly engaging an end of the valve stem, the stem engagement portion being in fluid communication with an internal receiver passage constructed and arranged for delivering fuel to the combustion chamber. The fuel cell adapter includes a collar projecting normally from the flange and dimensioned for slidingly accommodating reciprocal movement of the stem engagement portion and configured for protecting the valve stem against breakage.